MANE · Veradermics, Inc · Financials
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. ... As of June 30, 2026, we had $819.9 million in cash, cash equivalents and marketable securities. We expect our existing cash, cash equivalents and marketable securities will enable the Company to meet its obligations for at least the twelve-month period from the date the financial statements are available to be issued.”View the 10-Q filed Aug 11, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $62.07M | $23.28M | |
| $10.28M | $3.5M | |
| $72.35M | $26.78M | |
| -$72.35M | -$26.78M | |
| $0 | $585K | |
| $1.56M | $481K | |
| $2.35M | $290K | |
| -$70M | -$26.49M | |
| $0 | $0 | |
| -$70M | -$26.49M | |
| -$83.37M | -$27.3M | |
| -$69.94M | -$26.49M | |
| USD/shares | -$111.91 | -$37.05 |
| USD/shares | -$111.91 | -$37.05 |
| shares | 744.99K | 736.93K |
| shares | 744.99K | 736.93K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent operating lease liabilities | 2026-06-30 | USD 428,000 | 10-Q filed 2026-08-11 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 180 similar-size Biotechnology companies (of 559 listed).